AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Barclays in a research report issued to clients and investors on Monday, Digital Look reports. They currently have a £135 ($165.79) target price on the biopharmaceutical company’s stock. Barclays‘s target price indicates a potential upside of 33.66% from the stock’s previous close.
A number of other equities analysts also recently weighed in on AZN. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Friday. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Friday, September 22nd. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Monday, October 2nd. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 9th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of AstraZeneca in a research report on Tuesday, October 3rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of £118.05 ($144.97).
AstraZeneca Stock Performance
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Five stocks we like better than AstraZeneca
- How to Invest in the Healthcare Sector
- The most upgraded stocks in November have two things in common
- Transportation Stocks Investing
- Monday.com rocked earnings like it’s the weekend
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Plan to own one retailer? Make it this one
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.